MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Future oncology (London, England) Ročník 18; číslo 6; s. 639
Hlavní autori:	Cho, Byoung Chul, Felip, Enriqueta, Hayashi, Hidetoshi, Thomas, Michael, Lu, Shun, Besse, Benjamin, Sun, Tao, Martinez, Melissa, Sethi, Seema N, Shreeve, S Martin, Spira, Alexander I
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.02.2022
Predmet:	Acrylamides - adverse effects Acrylamides - therapeutic use Adolescent Adult Aniline Compounds - adverse effects Aniline Compounds - therapeutic use Antibodies, Bispecific - adverse effects Antibodies, Bispecific - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Clinical Trials, Phase III as Topic ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Morpholines - adverse effects Morpholines - therapeutic use Multicenter Studies as Topic Mutation Neoplasm Metastasis Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Randomized Controlled Trials as Topic Research Design Young Adult amivantamab tyrosine kinase inhibitors EGFR mutations lazertinib non-small-cell lung cancer
ISSN:	1744-8301, 1744-8301
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance mutations and mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for -mutant non-small-cell lung cancer.
Bibliografia:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
ISSN:	1744-8301 1744-8301
DOI:	10.2217/fon-2021-0923